Status:
COMPLETED
Thalidomide to Patients With Previously Untreated Multiple Myeloma
Lead Sponsor:
Norwegian University of Science and Technology
Collaborating Sponsors:
The Research Council of Norway
Nordic Myeloma Study Group, Germany
Conditions:
Multiple Myeloma
Eligibility:
All Genders
Phase:
PHASE3
Brief Summary
The purpose of this study is to test the effect of thalidomide in patients with multiple myeloma. The patients receive either thalidomide or a placebo tablet (neither patient nor doctor know which of ...
Detailed Description
Thalidomide has recently emerged as an effective treatment for patients with myeloma refractory to conventional chemotherapy. So far only limited experience is available on thalidomide for newly diagn...
Eligibility Criteria
Inclusion
- Patients with multiple myeloma in need of treatment
Exclusion
- Previous treatment against multiple myeloma
- Need of high dose chemotherapy with autologous stem cell support
- Women in fertile age
- Psychiatric disease or mental reduction leading to lack of cooperation
- Lack of consent
- Life expectancy below 3 months
- Active cancer of other etiology
Key Trial Info
Start Date :
January 1 2002
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
April 1 2007
Estimated Enrollment :
363 Patients enrolled
Trial Details
Trial ID
NCT00218855
Start Date
January 1 2002
End Date
April 1 2007
Last Update
March 7 2014
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Department of Haematology, St. Olavs hospital/NTNU
Trondheim, Norway, N-7006